Levin Capital Strategies L.P. Invests $664,000 in Evolent Health, Inc. (NYSE:EVH)

Levin Capital Strategies L.P. acquired a new position in shares of Evolent Health, Inc. (NYSE:EVH) in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 59,000 shares of the technology company’s stock, valued at approximately $664,000. Levin Capital Strategies L.P. owned approximately 0.05% of Evolent Health as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Royce & Associates LP acquired a new position in shares of Evolent Health during the 3rd quarter worth about $7,070,000. Foundry Partners LLC acquired a new position in shares of Evolent Health during the 3rd quarter worth about $10,042,000. Salem Investment Counselors Inc. boosted its position in shares of Evolent Health by 53.0% during the 4th quarter. Salem Investment Counselors Inc. now owns 350,155 shares of the technology company’s stock worth $3,939,000 after acquiring an additional 121,369 shares in the last quarter. Harbor Capital Advisors Inc. boosted its position in shares of Evolent Health by 140.0% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 422,421 shares of the technology company’s stock worth $11,946,000 after acquiring an additional 246,400 shares in the last quarter. Finally, Nordea Investment Management AB boosted its position in shares of Evolent Health by 7.0% during the 4th quarter. Nordea Investment Management AB now owns 130,453 shares of the technology company’s stock worth $1,469,000 after acquiring an additional 8,552 shares in the last quarter.

Analyst Ratings Changes

A number of analysts recently issued reports on EVH shares. Royal Bank of Canada decreased their target price on Evolent Health from $20.00 to $17.00 and set an “outperform” rating for the company in a research report on Tuesday, January 14th. Needham & Company LLC reissued a “buy” rating and issued a $15.00 target price on shares of Evolent Health in a research report on Friday, February 21st. Truist Financial decreased their target price on Evolent Health from $20.00 to $15.00 and set a “buy” rating for the company in a research report on Wednesday, January 22nd. Barclays decreased their target price on Evolent Health from $39.00 to $19.00 and set an “overweight” rating for the company in a research report on Monday, November 11th. Finally, BTIG Research decreased their target price on Evolent Health from $36.00 to $29.00 and set a “buy” rating for the company in a research report on Tuesday, December 3rd. One analyst has rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Evolent Health currently has a consensus rating of “Buy” and an average target price of $17.79.

Evolent Health Stock Up 3.5 %

EVH opened at $8.98 on Friday. The business has a 50 day moving average price of $10.61 and a two-hundred day moving average price of $18.33. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.58. The company has a market cap of $1.05 billion, a PE ratio of -10.95 and a beta of 1.45. Evolent Health, Inc. has a 52 week low of $8.40 and a 52 week high of $35.00.

Evolent Health (NYSE:EVH) last issued its earnings results on Thursday, February 20th. The technology company reported $0.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.38 by ($0.35). The business had revenue of $646.54 million for the quarter, compared to analysts’ expectations of $650.92 million. Evolent Health had a positive return on equity of 5.73% and a negative net margin of 2.41%. As a group, research analysts anticipate that Evolent Health, Inc. will post 0.08 EPS for the current year.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.